UK Medical Devices Agency (MDA) plans to manage increased demands
This article was originally published in Clinica
The UK's Medical Devices Agency expects a rise of 25% in 1996/97 in demands for clinical investigations which it will handle within the statutory deadline of 60 days. An expected increase in vigilance activities will also challenge the Agency, which predicts that the number of vigilance reports will double.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.